Halozyme Therapeutics | HALO - Прибыль до налогообложения





Прибыль до налогообложения Изменить Дата
Acadia Pharmaceuticals USD 46.47M 42.49M 2026-06
Agios Pharmaceuticals USD -99.11M 9.94M 2026-03
Alnylam Pharmaceuticals USD 177.81M 43.85M 2026-06
Amarin USD -852K 7.26M 2025-12
Amgen USD 2.08B 570M 2026-03
Baxter International USD 362M 368M 2026-06
Cara Therapeutics USD -6.8M 1.9M 2026-03
Cytokinetics USD -206.03M 23M 2026-03
DBV Technologies USD -47.4M 14.24M 2026-03
Eli Lilly USD 8.85B 583.8M 2026-03
Halozyme Therapeutics USD 180.33M 281.18M 2026-03
Intrexon USD -60.48M 27.09M 2024-06
Ionis Pharmaceuticals USD -114M 21M 2026-06
MannKind USD -16.37M 4.56M 2026-03
Minerva Neurosciences USD 22.51M 30.74M 2024-09
Nektar Therapeutics USD -43.09M 8.39M 2026-03
Pfizer USD -653M 5.84B 2026-06
Rigel Pharmaceuticals USD -1.03M 7.22M 2024-06
United Therapeutics USD 372.7M 54.4M 2026-06
Vanda Pharmaceuticals USD -22.92M 16.68M 2024-12